SCHEMBL3973316

SCHEMBL3973316

CNc1ccnn1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 12/20 0.56
CYP2C19 P33261 5/20 0.53
POLB P06746 2/20 0.52
CYP2C18 P33260 5/20 0.49
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
THPO P40225 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
CYP2C8 P10632 4/20 0.43
CYP1A2 P05177 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 2/20 0.40
MDM2 Q00987 1/20 0.39
NTRK1 P04629 3/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7006506 0.82 CYP2C9 (0.57) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL11274691 0.82 CYP2C9 (0.57) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL26546935 0.79 CYP2C9 (0.51) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL15834271 0.77 CYP2C9 (0.69) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL3433504 0.76 CYP2C9 (0.55) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL15283606 0.76 CYP2C9 (0.55) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL14973857 0.75 CYP2C9 (0.48) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL27676108 0.74 SOAT2 (0.52) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL9453146 0.73 SOAT1 (0.58) CYP2C9CYP2C19POLBCYP2C18LMNA
SCHEMBL15831219 0.73 CYP2C9 (0.64) CYP2C9CYP2C19POLBCYP2C18LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017196982-A1 BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RSV GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2017-11-16 WO disclosed
US-7625917-B2 S-o-(phenylaminocarbonyl)phenyl-substituted, especially with a quaternary onium group; enhanced antiviral activity and better reactivity with zinc finger moieties, particularly, the zinc finger on HIV-1's NCp7 nucleocapsid protein TURPIN JAMES A 2009-12-01 US disclosed
US-7625917-B2 S-o-(phenylaminocarbonyl)phenyl-substituted, especially with a quaternary onium group; enhanced antiviral activity and better reactivity with zinc finger moieties, particularly, the zinc finger on HIV-1's NCp7 nucleocapsid protein TURPIN JAMES A 2009-12-01 US disclosed
US-20090069571-A1 Process for the Preparation of 5-Alkylthioalkylamino-I-Phenyl-Pyrazoles MERIAL LIMITED 2009-03-12 US disclosed
US-20090069571-A1 Process for the Preparation of 5-Alkylthioalkylamino-I-Phenyl-Pyrazoles MERIAL LIMITED 2009-03-12 US disclosed
EP-1879869-B1 PROCESS FOR THE PREPARATION OF PRECURSORS OF 5-ALKYLTHIOALKYLAMINO-1-PHENYL-PYRAZOLES MERIAL LTD (US) 2009-01-14 EP disclosed
US-20080281107-A1 Process for the preparation of 5-alkylthioalkylamino-I-phenyl-pyrazoles MERIAL LIMITED 2008-11-13 US disclosed
US-20080281107-A1 Process for the preparation of 5-alkylthioalkylamino-I-phenyl-pyrazoles MERIAL LIMITED 2008-11-13 US disclosed
EP-1879869-A1 PROCESS FOR THE PREPARATION OF 5-ALKYLTHIOALKYLAMINO-1-PHENYL-PYRAZOLES Merial Limited (US) 2008-01-23 EP disclosed
WO-2006119862-A1 PROCESS FOR THE PREPARATION OF 5-ALKYLTHIOALKYLAMINO-1-PHENYL-PYRAZOLES MERIAL LTD. (US) 2006-11-16 WO disclosed
WO-2003020278-A1 CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES NOVARTIS AG (CH) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080281107-A1 Process for the preparation of 5-alkylthioalkylamino-I-phenyl-pyrazoles CYP3A5, CYP1A1, CYP3A4 CYP2C9 13/4885CYP2C19 9/4885POLB 1193/4885
US-20090069571-A1 Process for the Preparation of 5-Alkylthioalkylamino-I-Phenyl-Pyrazoles CYP3A5, CYP1A1, CYP3A4 CYP2C9 13/4885CYP2C19 9/4885POLB 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.